fulvestrant has been researched along with trametinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, DJ; Boland, GM; Cichowski, K; Crawford, L; Flaherty, KT; Frederick, DT; Herlyn, M; Krepler, C; Liberti, MV; Liu, X; Locasale, JW; Maertens, O; Magpusao, AN; Manchester, HE; McCall, SJ; Mukherjee, S; Singleton, KR; Sproesser, K; Stein, EM; Tingley, JP; Tsui, E; Wood, KC | 1 |
| Bussies, PL; Schlumbrecht, M | 1 |
2 other study(ies) available for fulvestrant and trametinib
| Article | Year |
|---|---|
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.
Topics: Antineoplastic Agents, Hormonal; Benzimidazoles; Cell Line, Tumor; Estradiol; Evolution, Molecular; Female; Fulvestrant; Humans; Imidazoles; Indoles; Male; Melanoma; Oximes; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Pyridones; Pyrimidinones; Quinolines; Signal Transduction; Sulfonamides | 2017 |
Dual Fulvestrant-Trametinib Therapy in Recurrent Low-Grade Serous Ovarian Cancer.
Topics: Female; Fulvestrant; Humans; Ovarian Neoplasms; Pyridones; Pyrimidinones | 2020 |